Your browser doesn't support javascript.
loading
The potential to backfill in phase I trials: the National Cancer Institute's Cancer Therapy Evaluation Program experience.
Foster, Jared C; Korn, Edward L; Freidlin, Boris; Moscow, Jeffrey A.
Affiliation
  • Foster JC; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Korn EL; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Freidlin B; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Moscow JA; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
JNCI Cancer Spectr ; 7(6)2023 10 31.
Article in En | MEDLINE | ID: mdl-38001028
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Neoplasms Limits: Humans Country/Region as subject: America do norte Language: En Journal: JNCI Cancer Spectr Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Neoplasms Limits: Humans Country/Region as subject: America do norte Language: En Journal: JNCI Cancer Spectr Year: 2023 Document type: Article Affiliation country: Country of publication: